Vistagen Therapeutics Inc (VTGN) Stock Analysis
Verdict: AVOID
Acute cash runway depletion (~5.5 months left) and post-hoc clinical repositioning expose VTGN to inevitable equity dilution.
Investment score: 18/100
Analysis as of
Is Vistagen Therapeutics Inc stock worth reviewing? The TradeMates thesis
Vistagen Therapeutics (VTGN) is a clinical-stage biotech microcap facing acute insolvency risks, with a trailing annual burn rate of $66.4M vs $30.8M in cash (giving ~5.5 months of runway), heavy analyst downgrades, and clinical data fails/exploratory re-analyses driving a 94% drawdown from 52-week highs.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 15/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 15/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
Vistagen Therapeutics Inc opportunities and risks
What speaks for VTGN
- Fasedienol Phase 3 Subgroup Signal
What speaks against VTGN
- Critical Cash Runway Depletion and Impending Dilution
Peers and competitors
- TOVX
- KALA
- BCLI
- AZTR
- XCUR
- APRE
- SNTI
- LNAI
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| VTGN | n/a | 5.2x | 0.0x | 84.6% | -2702.6% | -479.4% |
| TOVX | n/a | 35.4x | n/a | 92.0% | -3872.7% | -116.5% |
| KALA | n/a | 0.0x | n/a | 0.0% | 0.0% | -193.6% |
| BCLI | n/a | 0.0x | n/a | 0.0% | 0.0% | -37.6% |
| AZTR | n/a | 0.0x | 0.9x | 0.0% | 0.0% | -621.7% |
| XCUR | n/a | 0.0x | n/a | 0.0% | 0.0% | -83.5% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -116.5% |
Frequently asked questions about Vistagen Therapeutics Inc (VTGN)
Is VTGN stock a good investment?
The TradeMates model rates Vistagen Therapeutics Inc as AVOID with an investment score of 18/100. Vistagen Therapeutics (VTGN) is a clinical-stage biotech microcap facing acute insolvency risks, with a trailing annual burn rate of $66.4M vs $30.8M in cash (giving ~5.5 months of runway), heavy analyst downgrades, and clinical data fails/exploratory re-analyses driving a 94% drawdown from 52-week highs. This is algorithmic model output, not personal investment advice.
Is VTGN stock a buy?
The TradeMates model verdict for VTGN is AVOID with an investment score of 18/100. Treat this as a model signal to review, not a personal buy recommendation.